Phio Pharmaceuticals Corp. to Present at the Virtual Non-Deal Roadshow Series
Presentation Details
Thursday, September 5, 2024
Marlborough, Massachusetts–(Newsfile Corp. – August 29, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, announced today that management will present in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc. Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present on Thursday, September 5, 2024, at 12 PM EDT.
This exciting event will provide investors and stakeholders with the opportunity to learn more about Phio Pharmaceuticals’ innovative approach to gene silencing technology and its potential impact on cancer treatment. Mr. Bitterman will discuss the company’s latest developments, future plans, and strategic milestones.
Attendees can expect a comprehensive overview of Phio Pharmaceuticals’ cutting-edge research and how it is revolutionizing the field of biotechnology. The live presentation will be followed by a Q&A session, giving participants the chance to engage with management and gain valuable insights into the company’s progress.
Impact on Individuals
For individual investors, Phio Pharmaceuticals’ participation in the Virtual Non-Deal Roadshow Series presents a unique opportunity to gain firsthand knowledge about the company’s groundbreaking technology and potential for growth. By attending the presentation and Q&A session, investors can make informed decisions about supporting Phio Pharmaceuticals and participating in the advancement of innovative cancer treatments.
Impact on the World
Phio Pharmaceuticals’ commitment to developing advanced gene silencing technology has the potential to revolutionize cancer treatment on a global scale. By enhancing the effectiveness of immune cells in targeting and destroying tumor cells, Phio Pharmaceuticals’ INTASYL® siRNA technology could lead to more successful outcomes for cancer patients worldwide. The company’s participation in the Virtual Roadshow Series highlights its dedication to advancing the field of biotechnology and making a meaningful impact on the fight against cancer.
Conclusion
Phio Pharmaceuticals Corp.’s upcoming presentation at the Virtual Non-Deal Roadshow Series is a significant milestone that showcases the company’s commitment to innovation and excellence in the biotechnology sector. By sharing their groundbreaking research and strategic vision with investors and stakeholders, Phio Pharmaceuticals is paving the way for new advancements in cancer treatment that have the power to benefit individuals and communities around the world.
